Abstract 3414
Background
Angiosarcoma (AS) is a rare malignancy with a heterogeneous clinical presentation and genetic background. Different clinical AS subtypes can be envisaged, including: visceral, deep-seated soft tissue (ST), radiation induced (RT) and UV associated (UV) origin. To better understand their distinct biology and clinical outcome we investigated DNA methylation profiles, chromosomal stability and survival of these four subtypes.
Methods
After ethical approval, FFPE samples of AS from visceral, ST, RT and UV origin were collected from a nationwide search by the Dutch nationwide network and registry of histo- and cytopathology. DNA was extracted for methylation profiling with the Illumina Infinium MethylationEPIC array (German Cancer Research Center, Heidelberg, Germany). Quality control and unsupervised hierarchical clustering based on the 1% most varying methylation probes took place at Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. Copy number profiles were generated for chromosomal stability assessment. Anonymized clinical data were obtained from the Netherlands Cancer Registry.
Results
DNA methylation profiling and unsupervised hierarchical clustering of 36 AS samples (6 visceral, 5 ST, 14 RT, 11 UV), revealed two main clusters (A and B) and four subclusters (Table). The different clusters corresponded with clinical origin, showing enrichment of UV cases in cluster A1 and RT cases in cluster A2. Cluster A showed significantly more chromosomal aberrations and better median overall survival compared to cluster B (22.2 vs 5.5 months, p = 0.046).Table:
1711P Cluster characteristics
Cluster | A1 | A2 | B1 | B2 |
---|---|---|---|---|
Patients | 7 | 11 | 7 | 11 |
Subtype | 7 UV | 10 RT, 1 ST | 4 ST, 3 Visceral | 4 RT, 4 UV, 3 Visceral |
Median survival (months, range) | 22 (2-106) | 23 (1-281) | 4 (2-55) | 7 (0-40) |
Conclusions
In this novel DNA methylation profiling study, we demonstrated for the first time four different AS clusters. These clusters strongly correlated with clinical origin, chromosomal stability and overall survival. Further research is warranted in a larger patient cohort to better define the clinical significance of the different clusters.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
HDKT (Honderdduizend Keer een Tientje).
Disclosure
I.M.E. Desar: Research grant / Funding (institution): Novartis. W.T. van der Graaf: Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Bayer. All other authors have declared no conflicts of interest.
Resources from the same session
3371 - Pulmonary Resectable Metastases of Osteosarcoma With Apatinib and CHemotherapy (PROACH):A Multi-Center Phase II Randomized Clinical Trial
Presenter: Qiyuan Bao
Session: Poster Display session 1
Resources:
Abstract
1666 - National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis, AF (ALTITUDES)
Presenter: Thomas Ryckewaert
Session: Poster Display session 1
Resources:
Abstract
5531 - Health-related quality Of Life In patients with advanced Soft TIssue sarcomas treated with Chemotherapy: The HOLISTIC study
Presenter: Eugenie Younger
Session: Poster Display session 1
Resources:
Abstract
5568 - Assessing QUality of life and Experiences of diagnostic Trajectories of Sarcoma patients: The QUEST study protocol
Presenter: Vicky Soomers
Session: Poster Display session 1
Resources:
Abstract